［1］ OSTROM QT,PRICE M,NEFF C,et al.CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019［J］.Neuro Oncol,2022,24(5):1-95.
［2］ YANG K,WU Z,ZHANG H,et al.Glioma targeted therapy:insight into future of molecular approaches［J］.Mol Cancer,2022,21(1):39.
［3］ LOUIS DN,PERRY A,WESSELING P,et al.The 2021 WHO classification of tumors of the central nervous system:a summary［J］.Neuro Oncol,2021,23(8):1231-1251.
［4］ CHEN F,WENDL MC,WYCZALKOWSKI MA,et al.Moving pan-cancer studies from basic research toward the clinic［J］.Nat Cancer,2021,2(9):879-890.
［5］ ZHANG Y,XIAO Y,LI GC,et al.Long non-coding RNAs as epigenetic mediator and predictor of glioma progression,invasiveness,and prognosis［J］.Semin Cancer Biol,2022,83:536-542.
［6］ HU G,TANG Q,SHARMA S,et al.Expression and regulation of intergenic long non-coding RNAs during T cell development and differentiation［J］.Nat Immunol,2013,14(11):1190-1198.
［7］PINSON H,SILVERSMIT G,VANHAUWAERT D,et al.Epidemiology and survival of adult-type diffuse glioma in Belgium during the molecular era［J］.Neuro Oncol,2024,26(1):191-202.
［8］HAN S,CHEN X,HUANG L,et al.The tumor therapeutic potential of long non-coding RNA delivery and targeting［J］.Acta Pharm Sin B,2023,13(4):1371-1382.
［9］ GUTTMAN M,AMIT I,GARBER M,et al.Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals［J］.Nature(Basel),2009,458(7235):223-227.
［10］SOUREAS K,PAPADIMITRIOU MA,PANOUTSOPOULOU K,et al.Cancer quiescence:non-coding RNAs in the spotlight［J］.Trends Mol Med,2023,29(10):843-858.
［11］ BAI S,GUO J,ZHANG H.A meta-analysis of the clinicopathological significance of the lncRNA MALAT1 in human gastric cancer［J］.Front Oncol,2024,13:1257120.
［12］ XU WW,JIN J,WU XY,et al.MALAT1-related signaling pathways in colorectal cancer［J］.Cancer Cell Int,2022,22(1):126.
［13］ XIONG J,LIAN W,ZHAO R,et al.METTL3/MALAT1/ELAVL1 axis promotes tumor growth in ovarian cancer［J］.Onco Targets Ther,2024,17:85-97.
［14］ BAI R,SHI Z,LI D,et al.Gene expression profile of human colorectal cancer identified NKTR as a biomarker for liver metastasis［J］.Aging,2022,14(16):6656-6667.
［15］CHEN W,TAN X,YANG Q,et al.MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis［J］.Cell Signal,2022,94:110326.
［16］ WANG J,WANG H,ZHANG Y,et al.Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA,MALAT1-induced tumourigenesis in liver cancer［J］.Cell Signal,2014,26(5):1048-1059.
［17］GOYAL B,YADAV SRM,AWASTHEE N,et al.Diagnostic,prognostic,and therapeutic significance of long non-coding RNA MALAT1 in cancer［J］.Biochim Biophys Acta Rev Cancer,2021,1875(2):188502.
［18］YU H,SHEN ZA,ZHOU YK,et al.Recent advances in predicting protein-lncRNA interactions using machine learning methods［J］.Curr Gene Ther,2022,22(3):228-244.
［19］ LIU N,WANG ZZ,ZHAO M,et al.Role of non-coding RNA in the pathogenesis of depression［J］.Gene,2020,735:144276.
［20］ CHENG H,ZHAO H,XIAO X,et al.Long non-coding RNA MALAT1 upregulates ZEB2 expression to promote malignant progression of glioma by attenuating miR-124［J］.Mol Neurobiol,2021,58(3):1006-1016.
［21］ MOMTAZMANESH S,REZAEI N.Long non-coding RNAs in diagnosis,treatment,prognosis,and progression of glioma:a state-of-the-art review［J］.Front Oncol,2021,11:712786.
［22］ MA KX,WANG HJ,LI XR,et al.Long non-coding RNA MALAT1 associates with the malignant status and poor prognosis in glioma［J］.Tumour Biol,2015,36(5):3355-3359.
［23］ LIAO K,LIN Y,GAO W,et al.Blocking lncRNA MALAT1/miR-199a/ZHX1 axis inhibits glioblastoma proliferation and progression［J］.Mol Ther Nucleic Acids,2019,18:388-399.
［24］ VAZIFEHMAND R,ALI DS,OTHMAN Z,et al.The evaluation expression of non-coding RNAs in response to HSV-G47△ oncolytic virus infection in glioblastoma multiforme cancer stem cells ［J］.Neurovirol,2022,28(4-6):566-582.
［25］XIONG Z,WANG L,WANG Q,et al.LncRNA MALAT1/miR-129 axis promotes glioma tumorigenesis by targeting SOX2［J］.Cell Mol Med,2018,22(8):3929-3940.
［26］ MA R,ZHANG BW,ZHANG ZB,et al.LncRNA MALAT1 knockdown inhibits cell migration and invasion by suppressing autophagy through miR-384/GOLM1 axis in glioma［J］.Eur Rev Med Pharmacol Sci,2020,24(5):2601-2615.
［27］ CAI T,LIU Y,XIAO J.Long non-coding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma［J］.Cancer Med,2018,7(4):1404-1415.
［28］ VOCE DJ,BERNAL GM,WU L,et al.Temozolomide treatment induces lncRNA MALAT1 in an NF-κB and p53 codependent manner in glioblastoma［J］.Cancer Res,2019,79(10):2536-2548.
［29］NEUWELT E,ABBOTT NJ,ABREY L,et al.Strategies to advance translational research into brain barriers［J］.Lancet Neurol,2008,7(1):84-96.
［30］ BLACK KL,NINGARAJ NS.Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor［J］.Cancer Control,2004,11(3):165-173.
［31］ MA J,WANG P,YAO Y,et al.Knockdown of long non-coding RNA MALAT1 increases the blood-tumor barrier permeability by up-regulating miR-140［J］.Biochim Biophys Acta,2016,1859(2):324-338.